ATE437889T1 - Chemokin-mucin fusionsproteine mit einer gpi- ankerdomäne und deren verwendung als tumor-immun- adjuvanzien oder in der geweberegeneration - Google Patents

Chemokin-mucin fusionsproteine mit einer gpi- ankerdomäne und deren verwendung als tumor-immun- adjuvanzien oder in der geweberegeneration

Info

Publication number
ATE437889T1
ATE437889T1 AT05026397T AT05026397T ATE437889T1 AT E437889 T1 ATE437889 T1 AT E437889T1 AT 05026397 T AT05026397 T AT 05026397T AT 05026397 T AT05026397 T AT 05026397T AT E437889 T1 ATE437889 T1 AT E437889T1
Authority
AT
Austria
Prior art keywords
gpi
cells
tissue regeneration
tumour
chemokine
Prior art date
Application number
AT05026397T
Other languages
English (en)
Inventor
Ralf Prof Dr Huss
Peter Nelson
Hermann-Josef Prof Dr Groene
Original Assignee
Apceth Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apceth Gmbh & Co Kg filed Critical Apceth Gmbh & Co Kg
Application granted granted Critical
Publication of ATE437889T1 publication Critical patent/ATE437889T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT05026397T 2005-12-02 2005-12-02 Chemokin-mucin fusionsproteine mit einer gpi- ankerdomäne und deren verwendung als tumor-immun- adjuvanzien oder in der geweberegeneration ATE437889T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05026397A EP1792914B1 (de) 2005-12-02 2005-12-02 Chemokin-Mucin Fusionsproteine mit einer GPI-Ankerdomäne und deren Verwendung als Tumor-Immun-Adjuvanzien oder in der Geweberegeneration

Publications (1)

Publication Number Publication Date
ATE437889T1 true ATE437889T1 (de) 2009-08-15

Family

ID=36047948

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05026397T ATE437889T1 (de) 2005-12-02 2005-12-02 Chemokin-mucin fusionsproteine mit einer gpi- ankerdomäne und deren verwendung als tumor-immun- adjuvanzien oder in der geweberegeneration

Country Status (7)

Country Link
US (1) US20120208769A1 (de)
EP (1) EP1792914B1 (de)
AT (1) ATE437889T1 (de)
AU (1) AU2006319440B2 (de)
CA (1) CA2631587C (de)
DE (1) DE602005015733D1 (de)
WO (1) WO2007062844A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009014382A2 (en) * 2007-07-23 2009-01-29 Postech Academy-Industry Foundation Cxcl11 adjuvant compositions and uses thereof
CN101654679B (zh) * 2009-04-16 2012-06-13 浙江省台州医院 一种抗肿瘤融合基因及其表达蛋白与应用
CN102221608A (zh) * 2011-04-06 2011-10-19 浙江大学医学院附属第一医院 一种抗体组合物及其应用
JP6322626B2 (ja) * 2012-06-08 2018-05-09 アルカーメス，インコーポレイテッド ムチン−ドメインポリペプチドリンカーを含む融合ポリペプチド
WO2016077249A1 (en) * 2014-11-10 2016-05-19 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for expressing polypeptides on the surface of cells
US11571462B2 (en) 2015-06-03 2023-02-07 The Medical College Of Wisconsin, Inc. Engineered CCL20 locked dimer polypeptide
AU2016271292B2 (en) 2015-06-03 2022-04-14 The Medical College Of Wisconsin, Inc. An engineered CCL20 locked dimer polypeptide
US20220112257A1 (en) * 2019-01-11 2022-04-14 Arbele Limited Mul tispecific prochemokine therapeutic proteins (park) and method of making and using thereof
WO2021087839A1 (zh) * 2019-11-07 2021-05-14 武汉华大吉诺因生物科技有限公司 肿瘤特异性多肽序列及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562347B1 (en) * 1998-03-12 2003-05-13 The United States Of America As Represented By The Department Of Health And Human Services Chemokine-tumor antigen fusion proteins as cancer vaccines
CA2458236A1 (en) * 2001-08-27 2003-03-06 Greenville Hospital System Gpi-anchored cytokines
EP1943332A4 (de) * 2005-10-14 2011-04-13 Medimmune Inc Zellpräsentation von antikörperbibliotheken

Also Published As

Publication number Publication date
EP1792914B1 (de) 2009-07-29
CA2631587C (en) 2013-01-15
AU2006319440A1 (en) 2007-06-07
US20120208769A1 (en) 2012-08-16
CA2631587A1 (en) 2007-06-07
AU2006319440B2 (en) 2012-02-09
DE602005015733D1 (de) 2009-09-10
EP1792914A1 (de) 2007-06-06
WO2007062844A1 (en) 2007-06-07

Similar Documents

Publication Publication Date Title
ATE437889T1 (de) Chemokin-mucin fusionsproteine mit einer gpi- ankerdomäne und deren verwendung als tumor-immun- adjuvanzien oder in der geweberegeneration
Thomas et al. Implications of lymphatic transport to lymph nodes in immunity and immunotherapy
Rosalia et al. Use of enhanced interleukin-2 formulations for improved immunotherapy against cancer
JP7037480B2 (ja) がんの免疫療法のためのｎｋｇ２ｄ－ｉｇ融合タンパク質
Muller Leukocyte-endothelial cell interactions in the inflammatory response
WO2006047603A3 (en) Ungulates with genetically modified immune systems
KR20200046065A (ko) 암을 치료하기 위한 병용 면역 요법 및 사이토카인 조절 요법
BR112018067379A2 (pt) conjugado anticorpo-droga, composição, método para tratamento de um paciente que tem ou corre o risco de ter um câncer, para produzir o conjugado anticorpo-droga ou a composição, para determinar se um paciente será responsivo a um tratamento com o conjugado anticorpo-droga ou a composição, e, uso de um conjugado anticorpo-droga ou de uma composição.
GT200600517A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
PE20121643A1 (es) Polipeptidos del factor ix modificados y usos de los mismos
CY1119744T1 (el) Μια συνθεση που αποτελειται απο ογκο-σχετιζομενα πεπτιδια και ενα εμβολιο για την θεραπεια του γλοιοβλαστωματος και αλλων καρκινων
AR065289A1 (es) Antagonistas de activina - actriia y sus usos para la promocion del crecimiento oseo y el tratamiento de mieloma multiple
BR112018007982A2 (pt) composição, reação enzimática e método para preparar um copolímero de enxerto
JP2018522055A5 (de)
BR112012009973A2 (pt) promotor de regeneração de tecido usando recrutamento de células-tronco mesenquimais da medula óssea e/ou células-tronco pluripotentes em sangue
MA49207B1 (fr) Muteines d'interleukine 2 pour la propagation de lymphocytes t regulateurs
JP2019519215A5 (de)
CY1115774T1 (el) Υπερδιακλαδισμενα πολυανθρακικα για την διαλυτοποιηση δυσδιαλυτων δραστικων ουσιων
AR040753A1 (es) Composiciones de deposito de polimeros multimodales injectables y usos de las mismas
EP2829550A3 (de) Trimer-bildende Fusionsproteine
CY1109931T1 (el) Αναστολεις ομοιαζουσας με αγγειοποιητινη πρωτεϊνης 4, και η χρηση τους
EA200601738A1 (ru) Модифицированные белки буганины, цитотоксины и способы их применения
PE20080523A1 (es) Composiciones farmaceuticas topicas que comprenden un modificador de respuesta inmune
EP3414260A1 (de) Kombinationstherapie mit einem inflammatorischen immuncytokin und einer chimären antigenrezeptor(car)-t-zelle
MX2015016564A (es) Derivados de peptido similar al glucaton tipo 1 (glp-1) y uso de los mismos.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties